Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 44: EUROPA-Studie - Myokardinfarkt Abb. 45: EUROPA-Studie - Hospitalisierung Abb. 46: EUROPA-Studie - Blutdruck Aktuelles Bild - Abb. 47: EUROPA-Studie - Compliance Abb. 48: EUROPA-Studie - Non Compliance Abb. 49: EUROPA-Studie - Klinische Aussagen Abb. 50: EUROPA-Studie - KHK Zum letzten Bild
Abbildung 47: EUROPA-Studie - Compliance
After randomisation, study medication was well tolerated. At 3 years, 81 % of patients assigned perindopril and 84 % of placebo patients, were taking study medication. Most of the patients assigned to perindopril continued on 8 mg, only 7 % had dropped to 4 mg at 3 years. The average use of study medication was 3.7 years of 4.2 years follow-up.
 
EUROPA-Studie - Compliance
Vorheriges Bild Nächstes Bild   


Abbildung 47: EUROPA-Studie - Compliance
After randomisation, study medication was well tolerated. At 3 years, 81 % of patients assigned perindopril and 84 % of placebo patients, were taking study medication. Most of the patients assigned to perindopril continued on 8 mg, only 7 % had dropped to 4 mg at 3 years. The average use of study medication was 3.7 years of 4.2 years follow-up.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung